Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Astrana Health (ASTH)

Astrana Health: 2024 revenue up 47% to $2.03 billion, but net income fell

Mixed Impact 3 of 5 earnings Written later

Astrana Health reported fourth-quarter and full-year 2024 results. Revenue grew sharply, but net income attributable to Astrana fell from $60.7 million to $43.1 million for the year, and the fourth quarter swung to a $7.0 million net loss. The company also gave 2025 guidance of $2.5 billion to $2.7 billion in total revenue and $170 million to $190 million in Adjusted EBITDA.

Key points

  • Full-year 2024 total revenue was $2,034.5 million, up 47% from $1,386.7 million; diluted EPS was $0.90, versus $1.29 in 2023.
  • Fourth-quarter 2024 net loss attributable to Astrana was $7.0 million, compared with income of $12.4 million a year earlier, on revenue of $665.2 million, up 88%.
  • 2025 guidance: total revenue of $2,500 million to $2,700 million and Adjusted EBITDA of $170 million to $190 million, excluding acquisitions not yet closed.
  • On February 26, 2025, the company amended its credit agreement with Truist Bank, providing for $1.3 billion in total facilities including a $745.0 million delayed draw term loan.

The filing

CompanyAstrana Health (ASTH)
Form8-K, current report
Filed with the SECFeb 27, 2025, 4:34 PM ET
Accession number0001104659-25-018268

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.